Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/15/22
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 09/24/24
End: 10/31/32
Due: 10/31/33
Phase: N/A
Priority: Normal
Start: 04/11/23
End: 04/30/26
Due: 04/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors | NCT05599048 | Robert Bok, MD, PhD | user2@example.com | None | 2022-12-15 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |
| Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | NCT06391034 | Robert Bok, MD, PhD | user2@example.com | None | 2024-09-24 | 2032-10-31 | 2033-10-31 | - | - | 2025-07-14 |
| Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma | NCT05851378 | Robert Bok, MD, PhD | user2@example.com | None | 2023-04-11 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |